Amgen Inc (AMGN)

270.10
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    270.10/270.60
  • Day's Range:
    270.10 - 272.65

AMGN Overview

Prev. Close
269.9
Day's Range
270.1-272.65
Revenue
26.19B
Open
271.45
52 wk Range
185.72-294.7
EPS
12.54
Volume
0
Market Cap
144.34B
Dividend (Yield)
7.76
(2.72%)
Average Vol. (3m)
855
P/E Ratio
23.01
Beta
0.64
1-Year Change
44.41%
Shares Outstanding
533,579,206
Next Earnings Date
-
What is your sentiment on Amgen?
or
Vote to see community's results!

Amgen Inc News

Amgen Inc Analysis

Amgen Inc Company Profile

Amgen Inc Company Profile

Employees
24200
  • Type:Equity
  • Market:Germany
  • ISIN:US0311621009
  • WKN:867900

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Read More

Analyst Price Target

Average260.06 (-8.93% Downside)
High325.00
Low180.00
Price285.57
No. of Analysts25
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralStrong Buy
Technical IndicatorsNeutralBuyNeutralStrong SellStrong Buy
SummarySellNeutralSellSellStrong Buy
  • BTC
    1
    • gvx
      0
      • psps
        0
        • $BCRX
          0
          • hi
            0
            • hi dear
              0
          • hi
            0
            • hi
              0
              • new year's target 189
                0
                • 189???
                  0
              • crashing started playing betting
                0
                • ibsaa Mohammad123357
                  0